We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Hudson Hawk

10 December 2019 By Neil Unmack

The 108 bln euro drugmaker is cutting costs, exiting areas like diabetes, and hinting it might sell assets. It’s a bold but logical move to boost the group’s flagging sales. New CEO Paul Hudson’s main other task is to show he can shake off Sanofi’s mixed dealmaking track record.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)